Mark Socinski, MD, and Joshua Sabari, MD, discuss the treatment options for patients with KRASG12C mutated NSCLC with CNS metastases, and share advice for community oncologists treating this population.
EP. 1: Importance of Biomarker Testing in Patients with NSCLCDecember 21st 2022
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
EP. 2: Different Types of Biomarker Testing Methods Used in Patients with NSCLCJanuary 31st 2023
Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
EP. 4: Review of KRYSTAL 1b and Role of Adagrasib in Patients With Untreated CNS MetastasesFebruary 1st 2023
Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.
EP. 5: Use of Sotorasib in Patients with KRASG12C mutated NSCLCFebruary 1st 2023
Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.
EP. 6: Potential Shift of KRASG12C Inhibitors to the Front-line SettingFebruary 1st 2023
Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.